Key Points to Early Action for Preventing and Monitoring the Syndrome of Preeclampsia
Jialue Wang,Zi Yang
DOI: https://doi.org/10.1097/FM9.0000000000000100
2021-01-01
Maternal-Fetal Medicine
Abstract:Preeclampsia is a hypertensive disorder during pregnancy that threatens the health and life of the mother and fetus. The etiology and pathogenesis of preeclampsia is considered multifactorial, involving numerous mechanisms, pathways, and organ systems, which explains the disease heterogeneity observed in these patients.1 There is a Chinese idiom, “Bu Bu Wei Ying”, which means, advancing gradually and entrenching oneself at every step; and another Chinese saying, “Ceng Ceng She Fang”, which means, set up successive lines of defense. Therefore, it is essential to first thoroughly understand the different causes, pathogeneses, manifestations, and characteristics of preeclampsia from the genetic, cellular, tissue, organ, to multi-organ point of view. If the syndrome characteristics of preeclampsia can be deeply understood, then clinical insight into preeclampsia will be expanded in clinical practice of prevention, as well as monitoring during the whole pregnancy period. Accordingly, translating these findings to implement early preventative strategies in maternal-fetal medicine, particularly, early screening, early warning and detection, diagnosis, and monitoring of preeclampsia during gestation, can result in improved clinical decision making and outcomes. Taking a step-by-step approach and carrying out a hierarchical and classification strategy throughout pregnancy, prevention and careful monitoring of preeclampsia will improve the morbidity and mortality of both the mother and fetus.2 In depth understanding of the pathogenesis of preeclampsia involves multiple factors, mechanisms, and pathways Preeclampsia is widely recognized as a heterogeneous disease with multiple clinical manifestations and presentations.3 Underneath the surface between each case, the pathogenesis of preeclampsia is complex and multifactorial, involving various mechanisms and pathways.1,2 Different mediators have been found to be involved in the pathogenesis of preeclampsia in different risk groups. In a study conducted in the United States, patterns of early pregnancy serum biomarkers including placental growth factor (PlGF), soluble fms-like tyrosine kinase, endothelial factor (endoglin), selectin, tumor necrosis factor-α, vascular cell adhesion molecule, angiogenin, and human chorionic gonadotropin varied and mostly did not overlap between different high-risk groups such as those with chronic hypertension, diabetes, multiple gestation, and a history of preeclampsia. This data supports the hypothesis that numerous pathogenic mechanisms and pathways lead to preeclampsia.4 The different pathophysiological changes in every patient suggests there is even greater complexity at play in the pathogenesis of preeclampsia, which includes chronic uteroplacental ischemia, immune intolerance, lipoprotein toxicity, genetic imprinting, increased trophoblast apoptosis and necrosis, and excessive maternal inflammatory response to tolerant trophoblasts. Some characteristics in the clinical manifestation of women with preeclampsia were discovered by the early works of Zi Yang's team.5–11 The clinical manifestations of preeclampsia were complex, variety and changeable, and there was distinct involvement of important target end-organs among patients of different clinical phenotypes.5 Women with severe early-onset preeclampsia were more likely to have maternal liver and placental damage, and abnormal lipid metabolism regulation, especially those with liver damage. Therefore, long-chain fatty acid oxidation and metabolism disorders may be involved in the pathogenesis of severe early-onset preeclampsia.6,7 Based on clinical research, a platform to study the multifactorial pathogenesis of preeclampsia in animal models was further established. Disturbances in fatty acid oxidation, oxidative stress, and endothelial damage were initially investigated to explore the effects of different adverse factors to induce preeclampsia-like phenotypes in animal models. These studies found that adverse changes at different gestational periods can cause early and late preeclampsia-like phenotypes. Moreover, the manifestation of different types of early-onset preeclampsia have demonstrated inconsistent triggers and inducing factors involving endothelial dysfunction.8,9 Studies have revealed there are different mechanisms and pathways in the pathogenesis of preeclampsia, resulting in multi-systemic and distinct pathological changes and clinical manifestations, like “all roads lead to Rome”.2,5,10,11 No one single mechanism or pathway can entirely explain the heterogeneous pathogenesis in all preeclampsia. Although these patients show common clinical signs of hypertension, they present different clinical phenotypes, notably described as a subcategory or sub-type of preeclampsia in the literature. This alone suggests many independent pathogenic mechanisms or pathways at play. Examples of the heterogeneous pathogenesis involve different maternal physiological and pathological conditions, genetic makeup, environmental exposure such as diet and nutritional status and quality of prenatal care, disease onset, and various maternal-placental-fetal clinical features.10,11 In order to avoid the parable, “blind people touching the elephant”, that is to take part in the whole experience rather than a limited one, it is necessary to deeply understand the multiple factors, mechanisms, and pathways leading to the pathogenesis of preeclampsia. Furthermore, it is important to recognize preeclampsia from various clinical perspectives to find and implement markers for prevention and monitoring during every step in prenatal care. In the version of “Diagnosis and Treatment of Hypertension and Preeclampsia in Pregnancy: A clinical practice guideline in China (2020)”,12 this update emphasizes the heterogeneity of preeclampsia, its characteristics, and the different early warning signs, initial symptoms, and clinical manifestations that occur. To prevent and monitor preeclampsia, clinical insight should be expanded to improve early screening to detect early warning signs and processing ability, thus strengthening early diagnosis. Early prevention and monitoring of preeclampsia from different clinical perspectives Maternal deaths caused by preeclampsia are related to the prenatal care in each aspects, many of which are closely related to inadequate prenatal care and the failure to receive a timely diagnosis and treatment. It is internationally recognized that at least half of maternal deaths are preventable,13 and a majority of preeclampsia occurs in so-called normal pregnant women without any apparent clinical risk factors. Regardless whether there are inherent maternal risk factors, modifiable risk factors such as prenatal care, environmental exposure, and nutrition can be risk factors throughout pregnancy. Currently, calcium supplementation and low-dose aspirin for at-risk groups are widely accepted methods to prevent preeclampsia.14–16 However, the application of such measures has not prevented all preeclampsia. To prevent and monitor preeclampsia in early clinical practice, it is necessary to fully understand the pathogenic characteristics of preeclampsia from multiple various clinical viewpoints and perspectives, expand the clinical perspective on every basic primary point of prevention, and carry out adequate and standardized prenatal care for all pregnant women as early as possible from pre-pregnancy to delivery the whole gestational period.17 Identifying risk factors is key to early screening for preeclampsia The multiple factors, mechanisms, and pathways in the pathogenesis of preeclampsia reveal that no single predictive method or uniform preventative strategy can be effective in all patients. Early screening and intervention for mothers with risk factors associated with preeclampsia is the first step and a critical time point when preventing and monitoring preeclampsia.18 Maternal risk factors are important to note during early screening for preeclampsia. In recent years, guidelines for the diagnosis and management of preeclampsia in countries around the world, including China, the United States, the United Kingdom, Canada, and Australia, have pointed out a variety of maternal clinical risk factors associated with the increased probability of preeclampsia. Furthermore, these guidelines recommended that screening for preeclampsia should be carried out in the first trimester.12, 19–24 Preexisting or latent underlying medical diseases and pathological conditions, including hypertension, renal disease, diabetes, and autoimmune disorders (such as systemic lupus erythematosus and antiphospholipid syndrome), are high severe risk factors. A previous history of preeclampsia, multiple pregnancy gestation, and obesity are also considered to be high risk factors. The presence of risk factors in a current pregnancy (eg, diet, nutrition and so on) is considered to be moderate risk factors. A low-risk population refers to those who have experienced successful pregnancy without complications. Biomarkers such as biophysical parameters (eg, uterine artery pulsatility index) combined with biochemical parameters (eg, soluble fms-like tyrosine kinase-1, PlGF, and soluble endoglin) are useful when screening for preeclampsia. In both 2019 and 2020 guidelines, the American College of Obstetricians and Gynecologists association noted the importance of early screening of maternal risk factors for high-risk groups of preeclampsia. Those with any severe risk factors for preeclampsia or with more than one moderate risk factor are recommended to receive low-dose aspirin prophylaxis to prevent preeclampsia.18,19 In 2019, the International Federation of Obstetrics and Gynecology recommended early screening and prevention of early-onset preeclampsia. It stated that screening of early-onset preeclampsia in all singleton pregnancies is necessary and can be performed by a “Triple Test” or “Combined Test”, which includes assessing maternal risk factors, measuring mean arterial pressure and uterine artery pulsation index, and measuring serum PlGF between 11 and 13 weeks of pregnancy.25 These guidelines outline the need for the prediction and prevention of preeclampsia and suggests that obstetricians and midwives will have an important role in preventing preeclampsia during pregnancy, thus avoiding preeclampsia-related deaths. The screening for preeclampsia should be carried out as soon as possible. In 2005, the British Preeclampsia Community Guidelines emphasized that a preeclampsia risk assessment should be performed without delay, and different prenatal care plans should be formulated according to the existing preeclampsia risk factors. More importantly, early screening was further emphasized in the second version.26,27 In China, it is emphasized that screening for preeclampsia risk factors and necessary interventions must be conducted during the pre-pregnancy consultations and first prenatal visit. For those with preexisting internal diseases and pathological conditions, it is important that a standardized assessment and management be conducted by a multi-disciplinary team composed of relevant experts. For mothers with a history of preeclampsia, it is important to know the previous predisposing factors, disease onset time, and clinical and pathological type.28 It should be noted that further studies are still needed to elucidate uterine artery pulsation index and other serological markers for clinical application. In addition, preeclampsia classification studies are needed to prevent the over-treatment of particular phenotypes. Modifiable risk factors for preeclampsia should not be avoided Inadequate prenatal care, inappropriate dietary and nutritional factors, and adverse environmental factors are significant risk factors for preeclampsia, in addition to the inherent maternal risk factors.29 Moreover, these are modifiable risk factors that have been described to play a role in both early-onset and late-onset preeclampsia.5 Inadequate prenatal care is related to severe preeclampsia/eclampsia, associated adverse complications, and maternal death.30,31 Previous work of Zi Yang's team has suggested that the timing, quality, and hospital level of prenatal care has an impact on the onset of severe preeclampsia in China.28,29,32 The quantity of appointments cannot simply determine the effectiveness of prenatal care, but the quality of care. High-quality prenatal care includes early screening for risk factors and necessary intervention for pathogenic factors and underlying maternal pathological conditions and diseases.5 Individualized continuous perinatal care plans should be established for pregnant women with different risk factors and prognosis. Severe risk factors of preeclampsia should be thoroughly investigated during the first prenatal appointment, and appropriate preventive measures should be taken. Simultaneously, prenatal care should be actively modified by tailoring the number of outpatient prenatal care visits based on the initial assessment, rather than following the routine care plan with visits occurring every 2–4 weeks. The quality of care is especially important after 20 weeks of pregnancy.28 It has long been known that nutritional, dietary, and environmental factors are associated with preeclampsia, which can affect the mother, fetus, placenta, or as a whole. Deficiencies or disturbances in these factors not only promote preeclampsia but can also induce preeclampsia in women with genetic susceptibility. A high-fat diet; lack of vitamin D, calcium, and docosahexaenoic acid; and excessive weight gain during pregnancy (body mass index increase ≥3 kg/m2) have been associated with the pathogenesis of preeclampsia.33–36 In addition, the social environment and physical health of pregnant women have been implicated in the pathogenesis of preeclampsia. The occurrence of preeclampsia in normal pregnant women should not be overlooked. It is important for this population to access adequate prenatal care and be screened for risk factors such as dietary and nutritional deficiency and harmful environmental factors. When necessary, appropriate monitoring and timely intervention are influential strategies to prevent preeclampsia.37 Intervention for early warning signs of preeclampsia Early detection of preeclampsia risk factors is only one component in the prevention of preeclampsia. If the early warning signs of preeclampsia can be detected before the disease onset, it can be dealt with early and avoid subsequent complications associated with preeclampsia. This is recognized as the primary point of early intervention. Previous works of Zi Yang's team have revealed early warning signs before the onset of preeclampsia, including edema, excessive weight gain, mild increase in blood pressure, blood pressure fluctuations, prehypertension, a relative increase in blood pressure, fetal growth restriction, a trend towards fetal growth restriction, progressive decline in platelet count, thrombocytopenia, and hypoproteinemia.38,39 In recent years, the term “suspected preeclampsia” has appeared in the literature, which includes new-onset or worsening of existing hypertension; new-onset urine protein or increased original urine protein; one or more clinically suspected symptoms of preeclampsia such as epigastric pain, excessive edema or severe swelling (face, hands, feet), headaches, visual disturbances, sudden excessive weight gain (>1 kg/week in the third trimester); and signs related to preeclampsia including thrombocytopenia, elevated liver enzymes, fetal growth restriction suspicion, abnormal uterine artery pulsation index, or bilateral uterine artery notches.40–42 However, the criteria for suspected preeclampsia overlaps with the diagnostic criteria and clinical symptoms presented in preeclampsia, such that it may be already too late to intervene.37 A preventative approach earlier than looking for suspected preeclampsia is the observation of warning signs. For example, a trend towards fetal growth restriction is an early warning sign that may indicate placental-fetal impairment. This can be illustrated as a traffic light yellow signal for preeclampsia. Moreover, it is imperative to investigate the causes of the discovered warning signs in both mother and fetus. If these early warning signs can be treated, there is an increased likelihood preeclampsia can be prevented, or at least from manifesting to a more severe disease state.18,37 The emergence of early warning signs should invoke an investigation. Attention should be paid to tracking down subtle discrepancies despite the absence of adverse clinical manifestations. Continuation towards a full comprehensive examination should be conducted to assess other potential warning signs, and accordingly, the pregnant mother should be monitored with increased prenatal care visits.18,37,43 Thus, the prompt intervention of early warning signs may be of great benefit to halting the evolution of preeclampsia.37 Recognizing the diversity of the single initial symptom is a key point for early diagnosis Early diagnosis, intervention, and monitoring for early warning signs of preeclampsia, suspected preeclampsia, or mild preeclampsia can help reduce the clinical manifestations, thus preventing the disease from becoming severe. It is the most important thing that is to eliminate the disease in the germination state.18,37,43 The first isolated symptom of preeclampsia can simply present as hypertension or proteinuria. Other symptoms without hypertension or proteinuria can present as thrombocytopenia, pathological edema, fetal growth restriction, complaints of headache, upper abdominal discomfort and pain (especially upper right abdomen pain), vision changes, blurred vision, increased bleeding tendency, and other discomfort. Likewise, changes in laboratory results such as hypoproteinemia may also raise attention.44 For example, 16% of eclampsia cases do not have clinical hypertension, and 14% of eclampsia cases do not have proteinuria. Women with new-onset transient hypertension and proteinuria have a higher risk for preeclampsia (51% develop pregnancy hypertension or preeclampsia subsequently). Lastly, 25% to 50% of women diagnosed with gestational hypertension by only elevated blood pressure can progress to preeclampsia. Moreover, an earlier onset of gestational hypertension is associated with a higher the incidence of preeclampsia. The clinical course is heterogeneous for each individual with preeclampsia. The initial symptom can vary upon clinical presentation or laboratory indexes. Furthermore, the initial symptom in some patients may not present as hypertension or proteinuria, but rather end-organ damage or a single abnormality in their laboratory index. Currently, there is not enough information to intervene when only maternal hypertension and proteinuria appear. Therefore, it is crucial to comprehensively investigate and rigorously monitor the mother, placenta, and fetus as a whole after the discovery of the initial symptoms of preeclampsia. It is important to remember the day the disease is detected is not the day the disease began.18 Early warning information of preeclampsia for serious complications should not be overlooked Early warning signs are different in various stages of disease development in preeclampsia. Paying attention to the early warning signs that can potentially cause severe complications is the primary point of intervention to prevent severe preeclampsia. Many groups have tried to establish a scoring system to predict and evaluate the progress and severity of preeclampsia. For example, systemic vascular resistance Z-scores and uterine artery pulsation index Z-scores are used to predict and characterize the severity and progression of preeclampsia. It is believed that evaluating the maternal cardiovascular system may help define a subset of preeclampsia that have worse placental impairment. This may predict the likelihood of mild preeclampsia to progress towards increasing severity.45 The full- or mini-preeclampsia integrated estimate of risk (PIERS) is a model used to predict composite adverse maternal outcome. In PIERS, the predictive factors including self-conscious symptoms (eg, chest pain) and laboratory test indicators (eg, platelets, creatinine, transaminase) are believed to help identify cases of early-onset preeclampsia with a high risk of adverse outcomes. Therefore, these assessments may be important to guide a timely and effective intervention.46,47 Other similar severity scoring systems such as acute physiology and chronic health evaluation (APACHE)-II assess physiological parameters including body temperature, heart rate, blood pressure, arterial partial pressure of oxygen and carbon dioxide, oxygen flow, arterial pH, muscle rupture, and urea nitrogen. When combined with the age and chronic health status scores, this is believed to help assess the severity of preeclampsia and decide whether the patient needs to be transfer to the intensive care unit.48 However, these are relatively fixed models and lacks the specificity to accommodate the heterogeneous phenotype of preeclampsia, thus, may result in a delayed intervention. The identification and monitoring of the indices of end-organ damage should not be overlooked.2 The maternal organs, fetus, and placenta can be all affected, but the degree of impact and damage can vary in different types of preeclampsia and every individual. Previous work from Zi Yang's team has found that end-organ damage is mainly specific to the placenta and liver in early-onset preeclampsia.7 Furthermore, the incidence of placental damage is significantly higher when compared to late-onset preeclampsia. Although the placenta and fetus are affected in late-onset preeclampsia, the impact on the mother is more pronounced. This is particularly related to maternal cardiopulmonary and brain damage.7,37,49 Other groups have also found that the complications of early-onset and late-onset preeclampsia are different. Patients with early-onset preeclampsia are at severe risk for cardiopulmonary complications, renal failure, and placental abruption. Furthermore, perinatal and maternal mortality rates are also significantly increased.50,51 Preeclampsia may continue to progress and worsen in some patients during labor and after delivery. There have been cases of preeclampsia and eclampsia that only occur after delivery. There may also be iatrogenic eclampsia, heart failure, pulmonary edema, brain lesions, and even maternal death in these cases. Early warning signs for potential severe complications in preeclampsia are often not specific. For example, nausea, vomiting, and right upper abdominal pain are common in hemolysis, elevated liver enzymes, and low platelets syndrome (HELLP syndrome); persistent headaches, consciousness, and visual disturbances are common prodromal symptoms of hypertensive brain disease and eclampsia; and excessive weight gain and hyperreflexia may also be the first signs of eclampsia. Repeated unexplained abnormal fetal heart rate accompanied by threatened labor, unexplained spontaneous premature labor, high uterine tension, and continuous vaginal bleeding may be early signs of placental abruption. Based on different onset times, Zi Yang's team studied which organs were most likely to be impacted and which complications were most likely to occur in preeclampsia. Their work showed systolic and diastolic blood pressure were important factors in hypertensive encephalopathy and cardiovascular diseases, especially systolic blood pressure, which was closely related to the occurrence of hypertensive encephalopathy; obvious undulation of blood pressure and abnormal umbilical blood flow systolic/diastolic ratio were influencing factors for the occurrence of placental abruption; abnormal systolic/diastolic ratio was related to the incidence of fetal growth restriction and increased perinatal mortality; and cases with earlier onset of preeclampsia were more likely develop eclampsia and HELLP syndrome.37,49 Therefore, it is important to pay attention to the early warning signs that can progress into serious complications associated with preeclampsia. Once diagnosed, preventative measures and dynamic monitoring, the birth plan, and continued postpartum monitoring and control of preeclampsia-eclampsia are important elements to improve the morbidity and mortality of these patients. Summary Preeclampsia is a syndrome disease with heterogeneous that is considered complex and multifactorial, involving multiple mechanisms and pathways that manifest and present differently in every patient. Therefore, the occurrence and progression of preeclampsia should be examined from various perspectives and aspects. The first step to early action in preventing and monitoring preeclampsia starts from pre-pregnancy consultation and prenatal care in every step. Early screening and intervention should be prioritized at the first visit in early gestation during the peri-pregnancy period for primary prevention. The quality of prenatal care and close monitoring of dietary, nutritional, and environmental factors should be prioritized during pregnancy management. Early warning signs before disease onset and early isolated symptoms should not be overlooked but contribute to the early detection and diagnosis and intervention of preeclampsia. Lastly, early warning signs associated with serious complications of preeclampsia should be intervened during the management of preeclampsia. A hierarchical and classification approach should be carried out by “Bu Bu Wei Ying”, which means, advancing gradually and entrenching oneself at every step, and “Ceng Ceng She Fang”, which means, set up successive lines of defense. Using this method, preventative strategies can be employed before or at the onset of preeclampsia or during disease progression, ultimately reducing the incidence of maternal and fetal mortality and morbidity in this population.1,2,17,18 Funding None. Conflicts of Interest None.